PRPH Stock Overview
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States.
ProPhase Labs Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$11.39|
|52 Week High||US$15.25|
|52 Week Low||US$4.76|
|1 Month Change||-19.51%|
|3 Month Change||61.10%|
|1 Year Change||56.67%|
|3 Year Change||461.53%|
|5 Year Change||450.24%|
|Change since IPO||2,178.00%|
Recent News & Updates
We Think ProPhase Labs (NASDAQ:PRPH) Can Stay On Top Of Its Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
ProPhase Labs to license two investigational cancer compounds from Global BioLife
ProPhase Labs (NASDAQ:PRPH) on Thursday said its unit had entered into a licensing agreement with Global BioLife for two inhibitors that can be used to treat multiple indications, with an initial focus on cancer. As per the deal, PRPH unit ProPhase BioPharma obtained exclusive worldwide rights to develop and commercialize the inhibitors - LB-1 and LB-2 - for the treatment of cancer, inflammatory diseases and memory-robbing diseases. PRPH said it will evaluate LB-1 as a potential co-therapy with cancer drugs Taxol, doxorubicin, topotecan and cisplatin. The company also said that its revenue and earnings for Q2 rose Y/Y and will also grow in Q3. PRPH stock was marginally lower in the first few minutes of trading.
|PRPH||US Pharmaceuticals||US Market|
Return vs Industry: PRPH exceeded the US Pharmaceuticals industry which returned 1.8% over the past year.
Return vs Market: PRPH exceeded the US Market which returned -12.8% over the past year.
|PRPH Average Weekly Movement||14.1%|
|Pharmaceuticals Industry Average Movement||11.8%|
|Market Average Movement||7.9%|
|10% most volatile stocks in US Market||17.1%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: PRPH is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: PRPH's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
ProPhase Labs Fundamentals Summary
|PRPH fundamental statistics|
Is PRPH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PRPH income statement (TTM)|
|Cost of Revenue||US$49.56m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 11, 2022
|Earnings per share (EPS)||1.13|
|Net Profit Margin||15.91%|
How did PRPH perform over the long term?See historical performance and comparison
2.6%Current Dividend Yield
Is PRPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PRPH?
Other financial metrics that can be useful for relative valuation.
|What is PRPH's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does PRPH's PE Ratio compare to its peers?
|PRPH PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
JUSH.F Jushi Holdings
SLGL Sol-Gel Technologies
ELTP Elite Pharmaceuticals
PRPH ProPhase Labs
Price-To-Earnings vs Peers: PRPH is good value based on its Price-To-Earnings Ratio (10.1x) compared to the peer average (16.8x).
Price to Earnings Ratio vs Industry
How does PRPH's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Earnings vs Industry: PRPH is good value based on its Price-To-Earnings Ratio (10.1x) compared to the US Pharmaceuticals industry average (19.3x)
Price to Earnings Ratio vs Fair Ratio
What is PRPH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||10.1x|
|Fair PE Ratio||7.2x|
Price-To-Earnings vs Fair Ratio: PRPH is expensive based on its Price-To-Earnings Ratio (10.1x) compared to the estimated Fair Price-To-Earnings Ratio (7.2x).
Share Price vs Fair Value
What is the Fair Price of PRPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: PRPH ($11.39) is trading below our estimate of fair value ($66.24)
Significantly Below Fair Value: PRPH is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
How is ProPhase Labs forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PRPH's earnings are forecast to decline over the next 3 years (-67.9% per year).
Earnings vs Market: PRPH's earnings are forecast to decline over the next 3 years (-67.9% per year).
High Growth Earnings: PRPH's earnings are forecast to decline over the next 3 years.
Revenue vs Market: PRPH's revenue is expected to decline over the next 3 years (-17% per year).
High Growth Revenue: PRPH's revenue is forecast to decline over the next 3 years (-17% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PRPH's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has ProPhase Labs performed over the past 5 years?
Past Performance Score4/6
Past Performance Score 4/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PRPH has high quality earnings.
Growing Profit Margin: PRPH became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: PRPH has become profitable over the past 5 years, growing earnings by 42.9% per year.
Accelerating Growth: PRPH has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: PRPH has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.5%).
Return on Equity
High ROE: PRPH's Return on Equity (26.7%) is considered high.
Discover strong past performing companies
How is ProPhase Labs's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: PRPH's short term assets ($72.6M) exceed its short term liabilities ($19.8M).
Long Term Liabilities: PRPH's short term assets ($72.6M) exceed its long term liabilities ($13.5M).
Debt to Equity History and Analysis
Debt Level: PRPH has more cash than its total debt.
Reducing Debt: Insufficient data to determine if PRPH's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: PRPH's debt is well covered by operating cash flow (181.7%).
Interest Coverage: PRPH's interest payments on its debt are well covered by EBIT (73.4x coverage).
Discover healthy companies
What is ProPhase Labs's current dividend yield, its reliability and sustainability?
Dividend Score 2/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: PRPH's dividend (2.63%) is higher than the bottom 25% of dividend payers in the US market (1.52%).
High Dividend: PRPH's dividend (2.63%) is low compared to the top 25% of dividend payers in the US market (4.09%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, PRPH has been paying a dividend for less than 10 years.
Growing Dividend: PRPH's dividend payments have increased, but the company has only paid a dividend for 3 years.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (35.8%), PRPH's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ted Karkus (63 yo)
Mr. Ted William Karkus has served as the Chief Executive Officer of ProPhase Labs, Inc. since June 2009. Mr. Karkus founded 2001 Forrester Financial LLC and served as its Managing Member. He is a Managemen...
CEO Compensation Analysis
Compensation vs Market: Ted's total compensation ($USD941.40K) is below average for companies of similar size in the US market ($USD1.67M).
Compensation vs Earnings: Ted's compensation has been consistent with company performance over the past year.
Experienced Management: PRPH's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.
Experienced Board: PRPH's board of directors are seasoned and experienced ( 10.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.5%.
ProPhase Labs, Inc.'s employee growth, exchange listings and data sources
- Name: ProPhase Labs, Inc.
- Ticker: PRPH
- Exchange: NasdaqCM
- Founded: 1989
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$178.653m
- Shares outstanding: 15.69m
- Website: https://www.prophaselabs.com
Number of Employees
- ProPhase Labs, Inc.
- 711 Stewart Avenue
- Suite 200
- Garden City
- New York
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/06 00:00|
|End of Day Share Price||2022/08/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.